Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined vs Single Aesthetic Treatment with Dysport and Restylane
NCT02297516Phase 4Completed
- Sponsor
- Galderma
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, single-blind trial of botulinum toxin type A in glabellar lines, periorbital wrinkles and nasolabial folds (2 arms), sponsored by Galderma. Primary endpoint: Percentage of Subjects With Improvement in Global Facial Aesthetic Appearance at 7 months. Started Nov 2014; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar linesperiorbital wrinklesnasolabial folds
Beyond the preview
Go deeper on NCT02297516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297516.